(NASDAQ: GMDA) Gamida Cell's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.55%.
Gamida Cell's revenue in 2022 is $0.On average, 3 Wall Street analysts forecast GMDA's revenue for 2022 to be $3,028,666,814, with the lowest GMDA revenue forecast at $256,570,155, and the highest GMDA revenue forecast at $8,086,755,600. On average, 3 Wall Street analysts forecast GMDA's revenue for 2023 to be $1,207,498,281, with the lowest GMDA revenue forecast at $779,301,874, and the highest GMDA revenue forecast at $1,882,313,757.
In 2024, GMDA is forecast to generate $4,346,706,068 in revenue, with the lowest revenue forecast at $4,346,706,068 and the highest revenue forecast at $4,346,706,068.